New treatments for sleep apnoea
Tirzepatide, hypoglossal nerve stimulation and drug therapy for obstructive sleep apnoea.
Key point
Pharmacological therapy is not routine OSA treatment; dual GIP/GLP-1 agonists such as tirzepatide may be considered adjunctively for obese moderate-to-severe OSA.
From: [Guidelines for the diagnosis and treatment of obstructive sleep apnea in adults (2025)] (Zhonghua Jie He He Hu Xi Za Zhi, 2026 Mar 12) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 7, 6, 13, 8, 24.
New guidelines and consensus this year
- Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause SocietyMaturitas2026 Oct
- Pharmacologic Treatments With Lifestyle Modifications in Nonpregnant Adults With Overweight or Obesity in Outpatient Settings: A Living Clinical Guideline From the American College of Physicians (April 2026)Ann Intern Med2026 Aug
- Joint TOS/OMA/OAC Expert Guidance Statement on the Pharmacological Management of United States Adults With Overweight or Obesity Using the GRADE ApproachObesity (Silver Spring)2026 Apr
- [Guidelines for the diagnosis and treatment of obstructive sleep apnea in adults (2025)]Zhonghua Jie He He Hu Xi Za Zhi2026 Mar 12
- Hypoglossal nerve stimulation in the treatment of obstructive sleep apnea: Update on French practices and position paper of the SFRMS, SPLF and SFORL sleep medicine work-groupEur Ann Otorhinolaryngol Head Neck Dis2026 Jan
All papers from the last 12 months
253 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Clinical practice patterns and unmet needs in the use of GLP-1 receptor agonists in sleep medicine: A pan-European survey performed in the European sleep apnoea database networkPulmonology2026 DecPMID 42639925
- Enhancing economic modelling in obesity: integrating novel type 2 diabetes progression & obstructive sleep apnea remission - a UK case studyJ Med Econ2026 DecPMID 42021523
- Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trialJ Med Econ2026 DecPMID 42012820
- Current review of glucagon-like peptide 1 receptor agonists and risk of nonarteritic anterior ischemic optic neuropathyJ Endocr Soc2026 NovPMID 42857401Review
- From adiposity to multisystem morbidity: the case for weight loss as disease modificationLancet Diabetes Endocrinol2026 NovPMID 42660161Review
- Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6-Month Claims Database AnalysisDiabetes Obes Metab2026 NovPMID 42575714
- Changes in Hypoxia-Related Metrics With Hypoglossal Nerve Stimulation: A Scoping ReviewLaryngoscope2026 NovPMID 42210598Review
- Medical treatments for obesity: what does the future have in store?J Clin Endocrinol Metab2026 Oct 16PMID 42444567Review
- Changes in patient-reported outcomes and objective assessments based on baseline symptom severity in SURMOUNT-OSA: post-hoc analysesSleep2026 Oct 13PMID 42412744RCT
- The evolving role of metabolic and bariatric surgery in contemporary clinical practiceEur J Prev Cardiol2026 Oct 13PMID 41453132Review
More pulmonology trends
All specialties →High-flow nasal oxygen
High-flow nasal oxygen in acute hypoxaemic respiratory failure.
Key point: HFNC is strongly recommended for adults with acute hypoxemic respiratory failure, with close monitoring for escalation, based primarily on reduced need for intubation.
Biologics in COPD
Dupilumab and other biologics for COPD with type 2 inflammation.
Key point: Pooled analyses suggest dupilumab and mepolizumab consistently reduce moderate-to-severe exacerbations in eosinophilic or type 2 inflammatory COPD.
Bronchiectasis
Non-cystic fibrosis bronchiectasis and its newer treatments.
Robotic and navigational bronchoscopy
Robotic and navigation bronchoscopy to biopsy peripheral lung nodules.
Antifibrotics in pulmonary fibrosis
Nintedanib, pirfenidone and newer antifibrotics.
Biologics in severe asthma
Biologic therapies for severe asthma.
Key point: Biologic choice in adult severe asthma can be impacted by quality of life impairment, lung function, exacerbation frequency, oral corticosteroid use, endotype, biomarkers and comorbidities.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
("obstructive sleep apnea"[tiab] OR "obstructive sleep apnoea"[tiab]) AND (tirzepatide[tiab] OR "hypoglossal nerve stimulation"[tiab] OR aroxybutynin[tiab] OR "GLP-1"[tiab])Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.